Company news: Lupin

| Updated on September 13, 2019

Lupin has received approval for its propranolol hydrochloride extended-release (ER) capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. Lupin is the first generic company to receive an approval for generic Inderal-LA capsules for the Canadian market and the product has been approved and will be manufactured from Lupin’s Pithampur Unit-2 facility. The medicine is for the treatment of hypertension and for the prophylaxis of angina pectoris. Shares of Lupin closed 0.64 per cent higher at ₹764 on the BSE.

Published on September 13, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like